Treatment of prostate cancer
AssigneesBoston Scientific Medical Device Limited, Northwestern University
InventorsMatthew Dreher, Samdeep Mouli, Riad Salem
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition into the prostatic vasculature. In some embodiments, an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate. In some embodiments, the β-radiation-emitting composition is delivered into the arterial vasculature of the prostate via a catheter. In some embodiments, the β-radiation-emitting composition comprises a suspension of the β-radiation-emitting particles in an aqueous liquid.
Claims14
A method of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition through a catheter into the arterial prostatic vasculature, wherein the β-radiation-emitting composition comprises β-radiation-emitting microspheres that have mean diameter of 10 to 50 μm, wherein the β-radiation-emitting-microspheres comprise insoluble glass microspheres having yttrium-90 (90Y) as a constituent of the glass, wherein the microspheres have a specific activity per microsphere of 50 to 2,000 Bq when administered, wherein from 5,000 to 30,000 microspheres per mL of prostate tissue are delivered, and wherein an absorbed dose of 60 Gy to 200 Gy is delivered from the β-radiation-emitting composition to the whole prostate gland.
A method of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition that comprises β-radiation-emitting microspheres through a catheter into the arterial vasculature of the prostate, wherein the urethral vasculature of the patient is constricted while delivering the β-radiation-emitting composition, wherein the β-radiation-emitting composition comprises β-radiation-emitting microspheres that have mean diameter of 10 to 50 μm, wherein the β-radiation-emitting-microspheres comprise insoluble glass microspheres having yttrium-90 (90Y) as a constituent of the glass, wherein the microspheres have a specific activity per microsphere of 50 to 2,000 Bq when administered, wherein from 5,000 to 30,000 microspheres per mL of prostate tissue are delivered, and wherein an absorbed dose of 60 Gy to 200 Gy is delivered from the β-radiation-emitting composition to the whole prostate gland.
A method of treating a patient in need of therapy for prostate cancer comprising embolizing the prostatic vasculature of the patient to isolate the prostatic arteries;
- and delivering a β-radiation-emitting composition that comprises β-radiation-emitting microspheres through a catheter into the arterial vasculature of the prostate, wherein the β-radiation-emitting composition comprises β-radiation-emitting microspheres that have mean diameter of 10 to 50 μm, wherein the β-radiation-emitting-microspheres comprise insoluble glass microspheres having yttrium-90 (90Y) as a constituent of the glass, wherein the microspheres have a specific activity per microsphere of 50 to 2,000 Bq when administered, wherein from 5,000 to 30,000 microspheres per mL of prostate tissue are delivered, and wherein an absorbed dose of 60 Gy to 200 Gy is delivered from the β-radiation-emitting composition to the whole prostate gland.
Dependencies are inferred from the claim text.